Morgan Stanley reaffirmed their equal weight rating on shares of Hikma Pharmaceuticals Plc (OTC:HKMPF) in a report released on Tuesday morning.

A number of other brokerages have also recently issued reports on HKMPF. Jefferies Group LLC cut shares of Hikma Pharmaceuticals Plc from a buy rating to an underperform rating in a research note on Wednesday, May 17th. Numis Securities Ltd reissued an add rating on shares of Hikma Pharmaceuticals Plc in a research note on Friday, May 19th. Finally, ValuEngine raised shares of Hikma Pharmaceuticals Plc from a hold rating to a buy rating in a research note on Thursday, July 27th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the company. The stock presently has an average rating of Hold and a consensus target price of $27.00.

Hikma Pharmaceuticals Plc (HKMPF) traded down 9.95% during trading on Tuesday, hitting $16.75. 100 shares of the stock were exchanged. The stock has a 50 day moving average of $20.10 and a 200-day moving average of $23.45. The stock has a market cap of $4.04 billion and a P/E ratio of 25.30. Hikma Pharmaceuticals Plc has a 52 week low of $16.75 and a 52 week high of $35.00.

COPYRIGHT VIOLATION NOTICE: This piece was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://www.dailypolitical.com/2017/08/09/morgan-stanley-reiterates-equal-weight-rating-for-hikma-pharmaceuticals-plc-otchkmpf.html.

About Hikma Pharmaceuticals Plc

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas.

Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.